Search Results for: Immunosuppressants

July 2, 2020July 2, 2020

Prior treatment with immunosuppressants among COVID-19 inpatients at one hospital in Spain.

Publication date: Jun 28, 2020 Vulnerability to coronavirus disease 2019 (COVID-19) in patients with cardiovascular risk factors is well known. However, the prognostic influence of immunosuppressive drugs or their ability ... Read more

June 26, 2020June 26, 2020

Etoposide treatment adjunctive to immunosuppressants for critically ill COVID-19 patients: Etoposide for severe COVID-19 patients.

Coronavirus Literature

Publication date: Jun 21, 2020 Concepts Keywords Etoposide RTT Immunosuppressants Lactones Hepatotoxins Etoposide Medical specialties Clinical medicine Medicine 7+3 Immunosuppressive drug Semantics Type Source Name drug DRUGBANK Etoposide disease MESH ... Read more

April 22, 2020April 22, 2020

Multiple Sclerosis Drugs Industry Assessment 2020: Immunomodulators, Immunosuppressants, Interferons and Others

Multiple Sclerosis News

Publication date: Apr 22, 2020 The growth of multiple sclerosis drugs market is aided by the support from government as well as non-government organization. Appropriate financial support from the government ... Read more

April 17, 2020April 17, 2020

Clinical characteristics and immunosuppressants management of coronavirus disease 2019 in solid organ transplant recipients.

Coronavirus Literature

Publication date: Apr 13, 2020 Over 1,000,000 cases of coronavirus disease 2019 (COVID-19) have been confirmed since the worldwide outbreak began. Not enough data on infected solid organ transplant (SOT) ... Read more

August 9, 2020August 9, 2020

Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment.

Multiple Sclerosis Literature

Publication date: Aug 06, 2020 Limited comparative effectiveness data for rituximab (RTX) versus natalizumab (NTZ), fingolimod (FTY), and dimethyl fumarate (DMF) for the treatment of multiple sclerosis (MS) exist. Clinician-reported ... Read more

August 8, 2020August 8, 2020

Age-Related Lymphocyte Output During Disease-Modifying Therapies for Multiple Sclerosis.

Multiple Sclerosis Literature

Publication date: Aug 06, 2020 Patients with multiple sclerosis exhibit the same qualitative and quantitative changes in immune system cells observed in aging. In the last 20 years, multiple sclerosis ... Read more

August 7, 2020August 7, 2020

MS breakthrough: New drug works better at preventing symptom relapses

Multiple Sclerosis News

Publication date: Aug 06, 2020 A new drug for multiple sclerosis (MS) is working better at preventing .. . Patients of MS normally suffer from muscle weakness, numbness, balance, .. ... Read more

August 7, 2020August 7, 2020

Attitudes of patients with relapsing-remitting form of multiple sclerosis using disease-modifying drugs in Montenegro regarding COVID-19 pandemic.

Multiple Sclerosis Literature

Publication date: Jul 06, 2020 In the days of the reorganization of healthcare systems due to SARS-Cov2 pandemic, patients suffering from chronic diseases are being often neglected. The aim of ... Read more

August 7, 2020August 7, 2020

Ofatumumab versus Teriflunomide in Multiple Sclerosis.

Multiple Sclerosis Literature

Publication date: Aug 06, 2020 Ofatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and B-cell activation. The relative effects ... Read more

August 6, 2020August 6, 2020

New Drug May Beat Older One at Preventing MS Relapse

Multiple Sclerosis News

Publication date: Aug 04, 2020 The drug, called ofatumumab, beat a standard MS medication in reducing patients’ symptom relapses. The researchers said the findings, published Aug. 6 in the New ... Read more